Targets › CTGF
1 program from 1 company in 1 trial: 1 Phase 4; Ophthalmology; next expected readout Jan 2032.
Major connective tissue mitoattractant secreted by vascular endothelial cells. Promotes proliferation and differentiation of chondrocytes. (UniProt, P29279)
Open in Phaseline: the race on CTGF, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Neurotech Pharmaceuticals | NT-501/revakinagene taroretcel-lwey Surgically implanted intraocular device expressing recombinant human ciliary neurotrophic | CTGF | Phase 4 | Macular Telangiectasia Type 2 (MacTel) | Jan 2032 |
Macular Telangiectasia Type 2 (MacTel) (1)
other (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.